![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DELPHI: Safety, tolerability and efficacy of darunavir/ritonavir over 48 weeks
in ARV treatment-experienced children and adolescents
Final analysis
|
|
|
Reported by Jules Levin
ICAAC/IDSA, Oct 27, 2008 Wash DC
S Blanche, R Bologna, P Cahn, S Rugina,
P Flynn, C Fortuny, P Vis, V Sekar,
B Van Baelen, S Spinosa-Guzman
DELPHI: Author Conclusions
Final Week 48 analysis
In treatment-experienced, HIV-1-infected children and adolescents aged 6-17 years, DRV/r showed
--comparable exposure to adults with appropriate dose selection
--favorable safety and tolerability
--positive changes in body weight
--good virologic response rates in the presence of <3 DRV resistance-associated mutations
DRV/r is a valuable therapeutic option for treatment-experienced, HIV-1-infected pediatric patients
![del-1.gif](../images/121108/del-1.gif)
![week-2.gif](../images/121108/week-2.gif)
![n80-3.gif](../images/121108/n80-3.gif)
![zscore-4.gif](../images/121108/zscore-4.gif)
![death-5.gif](../images/121108/death-5.gif)
![ae-6.gif](../images/121108/ae-6.gif)
![lipase-7.gif](../images/121108/lipase-7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|